Characteristics and natural history of early-stage cardiac transthyretin amylo
Dr Arnaud GALAT – Cardiologue – Hopital Prive Paul D’Egine – Champigny-sur-Marne Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35608040/ PMID : 35608040
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
Dr Olivier HUTTIN – Cardiologue CHU de Nancy Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35779241/ PMID : 35779241
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.
Dr Amira ZAROUI – Cardiologue APHP Henri Mondor – Créteil Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. https://pubmed.ncbi.nlm.nih.gov/31189919/ PMID : 31189919
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Dr Anne-Catherine POULEUR : Cardiologue – institut cardiovasculaire Saint Luc – Bruxelles BELGIQUE
Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.
Dr Silvia OGHINA : Cardiologue APHP Henri Mondor – Créteil Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. https://pubmed.ncbi.nlm.nih.gov/34888361/
Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.
Dr Vincent ALGALARRONDO : Cardiologue APHP Bichat – Paris Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35439584/
Prevalence and determinants of iron deficiency in cardiac amyloidosis.
Dr Benoît LEQUEUX : Cardiologue CHU de Poitiers Prevalence and determinants of iron deficiency in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35128833/. PMID : 35128833
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Pr François TOURNOUX : Cardiologue – CHU de Montréal CANADA Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). https://pubmed.ncbi.nlm.nih.gov/35451899/ PMID : 35451899
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])
Dr Zoubida TAZI MEZALEK – Cardiologue CHU de Rabat MAROC Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) https://pubmed.ncbi.nlm.nih.gov/33667442/ PMID : 33667442
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.
Dr Eve CARIOU – Cardiologue CHU de Toulouse Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. https://pubmed.ncbi.nlm.nih.gov/33129740/ PMID : 33129740